Back to discover
Drug

N,N-Dimethyltryptamine

In clinical development
Emerging researchEarly-to-mid developmentRising momentum
Also known as 2-(3-indolyl)ethyldimethylamine, 3-(2-dimethylaminoethyl)indole, DMT, Dimethyltryptamine+2 more

2-(3-indolyl)ethyldimethylamine, 3-(2-dimethylaminoethyl)indole, DMT, Dimethyltryptamine, N,N-dimethyl-1H-indole-3-ethylamine, N,-N-dimethyltryptamine.

7
Research papers
6
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Neural Effects of Continuous Intravenous Infusion of N,N-dimethyltryptamine (DMT)

Clinical trial2026-07-09Results expected Q3 2028 · ClinicalTrials.gov

Phase 1 Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

Clinical trial2026-06-16Results expected Q4 2027 · ClinicalTrials.gov

Investigation of Psychedelic Effects in Psychoactive Substances

Clinical trial2026-02-23Results expected Q2 2027 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
N,N-Dimethyltryptamine
Aliases & brands
2-(3-indolyl)ethyldimethylamine3-(2-dimethylaminoethyl)indoleDMTDimethyltryptamineN,N-dimethyl-1H-indole-3-ethylamineN,-N-dimethyltryptamine
RxNorm CUI
7207
ChEMBL ID
CHEMBL12420
UNII
WUB601BHAA

Clinical trials

14 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
14
registered trials across all phases
LATEST COMPLETION 2025
6
Active studies
5
Recruiting
2
Late-stage (III+)
7
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 14
Early Phase 11Phase 110Phase 21Phase N / A2

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

7 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20162025
Most influential
Recent papers
Major research themes8
Hallucinogens6N,N-Dimethyltryptamine2Autonomic Nervous System1Banisteriopsis1Creativity1Electrocardiography1Lysergic Acid Diethylamide1N-Methyl-3,4-methylenedioxyamphetamine1
Journals, researchers & institutions
Top journals
  • Journal of psychopharmacology (Oxford, England)2
  • Current neuropharmacology1
  • JAMA psychiatry1
  • Proceedings of the National Academy of Sciences of the United States of America1
  • Psychopharmacology1
  • The American journal of psychiatry1
Leading researchers
  • Carhart-Harris RL2
  • Nutt DJ2
  • Ramaekers JG2
  • Rosas FE2
  • Timmermann C2
  • Alamia A1
  • Antonio JH1
  • Arnfred S1
Leading institutions
free-text, unnormalised
  • Centre for Complexity Science2
  • Centre for Psychedelic Research2
  • Maastricht University2
  • University of California2
  • University of Sussex2
  • Center for Eudaimonia and Human Flourishing1

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 2 of the same disease areas as N,N-Dimethyltryptamine in the shared literature.

2 shared diseases3 shared papers

Studied across 2 of the same disease areas as N,N-Dimethyltryptamine in the shared literature.

2 shared diseases3 shared papers

Frequently co-studied with N,N-Dimethyltryptamine in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials